Search citation statements

Order By: Relevance

Paper Sections

Select...
4

Citation Types

1
37
0

Year Published

2007
2007
2024
2024

Publication Types

Select...
5
3

Relationship

0
8

Authors

Journals

citations
Cited by 80 publications
(38 citation statements)
references
References 19 publications
(20 reference statements)
1
37
0
Order By: Relevance
“…14 In the previous studies of IVIg treatment for patients with pemphigus, it was reported that the autoantibody titers did reduce during the treatment. 16 Rituximab was originally developed to treat refractory, low-grade, follicular, B cell non-Hodgkins lymphoma 2 , but has been used experimentally in various autoimmune diseases including autoimmune blistering disorders (pemphigus vulgaris, 5-7,9-10,12,14,17-27 pemphigus vegetans, 12 pemphigus foliaceus, 5,8,11,12,28 paraneoplastic pemphigus, [29][30][31][32][33] bullous pemphigoid, 34 and epidermolysis bullosa acquisita 13,35,36 …”
Section: Discussionmentioning
confidence: 99%
See 2 more Smart Citations
“…14 In the previous studies of IVIg treatment for patients with pemphigus, it was reported that the autoantibody titers did reduce during the treatment. 16 Rituximab was originally developed to treat refractory, low-grade, follicular, B cell non-Hodgkins lymphoma 2 , but has been used experimentally in various autoimmune diseases including autoimmune blistering disorders (pemphigus vulgaris, 5-7,9-10,12,14,17-27 pemphigus vegetans, 12 pemphigus foliaceus, 5,8,11,12,28 paraneoplastic pemphigus, [29][30][31][32][33] bullous pemphigoid, 34 and epidermolysis bullosa acquisita 13,35,36 …”
Section: Discussionmentioning
confidence: 99%
“…34 Epidermolysis bullosa acquisita is another subepidermal blistering disorder with antibodies against collagen VII, a component of the basement membrane zone, and is often recalcitrant to conventional treatment. 35 The autoimmune blistering disorders mentioned above are all conventionally treated with topical corticosteroids along with systemic corticosteroids and/or other systemic immunosuppressants. Most patients respond favorably to conventional regimens; however, a minority of patients fails and other treatment options must be considered.…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation
“…Recently, Schmidt et al[ 15] reported the case of a patient with recalcitrant EBA that responded to 4 courses of rituximab with a complete remission allowing a progressive discontinuation of colchicine and oral corticosteroids and a reduction of the dose of azathioprine.…”
Section: Discussionmentioning
confidence: 99%
“…In addition, rituximab has shown promise in single cases of recalcitrant epidermolysis bullosa acquisita [4,5] and mucous membrane pemphigoid [6] .…”
mentioning
confidence: 99%